Metabolism, variability and risk assessment.

For non-genotoxic carcinogens, "thresholded toxicants", Acceptable/Tolerable Daily Intakes (ADI/TDI) represent a level of exposure "without appreciable health risk" when consumed everyday or weekly for a lifetime and are derived by applying an uncertainty factor of a 100-fold to a no-observed-adverse-effect-levels (NOAEL) or to a benchmark dose. This UF allows for interspecies differences and human variability and has been subdivided to take into account toxicokinetics and toxicodynamics with even values of 10(0.5) (3.16) for the human aspect. Ultimately, such refinements allow for chemical-specific adjustment factors and physiologically based models to replace such uncertainty factors. Intermediate to chemical-specific adjustment factors are pathway-related uncertainty factors which have been derived for phase I, phase II metabolism and renal excretion. Pathway-related uncertainty factors are presented here as derived from the result of meta-analyses of toxicokinetic variability data in humans using therapeutic drugs metabolised by a single pathway in subgroups of the population. Pathway-related lognormal variability was derived for each metabolic route. The resulting pathway-related uncertainty factors showed that the current uncertainty factor for toxicokinetics (3.16) would not cover human variability for genetic polymorphism and age differences (neonates, children, the elderly). Latin hypercube (Monte Carlo) models have also been developed using quantitative metabolism data and pathway-related lognormal variability to predict toxicokinetics variability and uncertainty factors for compounds handled by several metabolic routes. For each compound, model results gave accurate predictions compared to published data and observed differences arose from data limitations, inconsistencies between published studies and assumptions during model design and sampling. Finally, under the 6(th) framework EU project NOMIRACLE (http://viso.jrc.it/nomiracle/), novel methods to improve the risk assessment of chemical mixtures were explored (1) harmonization of the use of uncertainty factors for human and ecological risk assessment using mechanistic descriptors (2) use of toxicokinetics interaction data to derive UFs for chemical mixtures. The use of toxicokinetics data in risk assessment are discussed together with future approaches including sound statistical approaches to optimise predictability of models and recombinant technology/toxicokinetics assays to identify metabolic routes for chemicals and screen mixtures of environmental health importance.

[1]  A. Ragas,et al.  Trends in human risk assessment of pharmaceuticals , 2007, Analytical and bioanalytical chemistry.

[2]  Philippe Verger,et al.  Combining analytical techniques, exposure assessment and biological effects for risk assessment of chemicals in food , 2009 .

[3]  M. Hammill,et al.  Tissue-Specific Contaminant Accumulation and Associated Effects on Hepatic Serum Analytes and Cytochrome P450 Enzyme Activities in Hooded Seals (Cystophora cristata) from the Gulf of St. Lawrence , 2009, Archives of environmental contamination and toxicology.

[4]  K Walton,et al.  An analysis of the need for an additional uncertainty factor for infants and children. , 2000, Regulatory toxicology and pharmacology : RTP.

[5]  K Walton,et al.  Pathway-Related Factors: The Potential for Human Data to Improve the Scientific Basis of Risk Assessment , 2001 .

[6]  A M J Ragas,et al.  Human and environmental risk assessment of pharmaceuticals: differences, similarities, lessons from toxicology , 2007, Analytical and bioanalytical chemistry.

[7]  K Walton,et al.  Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[8]  A G Renwick,et al.  Human variability and noncancer risk assessment--an analysis of the default uncertainty factor. , 1998, Regulatory toxicology and pharmacology : RTP.

[9]  J. Dorne,et al.  Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[10]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[11]  J. Larsen,et al.  The influence of thresholds on the risk assessment of carcinogens in food. , 2009, Mutation research.

[12]  Jean Lou Dorne,et al.  Meta-analysis of human toxicokinetic data: An innovative Bayesian approach and its application in human risk assessment , 2008 .

[13]  J. Dorne,et al.  The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  J. Dorne,et al.  Human variability in hepatic and renal elimination: implications for risk assessment , 2007, Journal of applied toxicology : JAT.

[15]  A G Renwick,et al.  Structure-based thresholds of toxicological concern--guidance for application to substances present at low levels in the diet. , 2005, Toxicology and applied pharmacology.

[16]  Joint Fao,et al.  Safety evaluation of certain contaminants in food , 2006 .

[17]  J. Dorne Impact of inter‐individual differences in drug metabolism and pharmacokinetics on safety evaluation , 2004, Fundamental & clinical pharmacology.

[18]  B. Ghanayem,et al.  Investigation of xenobiotics metabolism, genotoxicity, and carcinogenicity using Cyp2e1(-/-) mice. , 2007, Current drug metabolism.

[19]  E. Testai,et al.  Effect of lindane on CYP‐mediated steroid hormone metabolism in male mice following in utero exposure , 2009, Journal of applied toxicology : JAT.

[20]  John Christian Larsen,et al.  Scientific Opinion of the Panel on Contaminants in the Food Chain on a request from the European Commission on Polycyclic Aromatic Hydrocarbons in Food: Question N° EFSA-Q-2007-136 , 2008 .

[21]  K Walton,et al.  Default Factors for Interspecies Differences in the Major Routes of Xenobiotic Elimination , 2001 .

[22]  S. Fukushima,et al.  Concordance of thresholds for carcinogenicity of N-nitrosodiethylamine , 2006, Archives of Toxicology.

[23]  Geoff K Frampton,et al.  The effects on terrestrial invertebrates of reducing pesticide inputs in arable crop edges: a meta‐analysis , 2007 .

[24]  E. Hodgson,et al.  Metabolic interactions of agrochemicals in humans. , 2008, Pest management science.

[25]  W Slob,et al.  Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[26]  K Walton,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[27]  K Walton,et al.  Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  E. Testai,et al.  Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. , 2005, Toxicology and applied pharmacology.

[29]  K Walton,et al.  Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[30]  Lutz Edler,et al.  Risk assessment of substances that are both genotoxic and carcinogenic: Report of an International Conference organized by EFSA and WHO with support of ILSI Europe , 2006 .

[31]  J. Dorne,et al.  Human variability in glucuronidation in relation to uncertainty factors for risk assessment. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[32]  J. Dorne,et al.  Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[33]  J. Dorne,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[34]  J. Dorne,et al.  Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[35]  Hilde Kruse,et al.  Opinion of the Scientific Committee on "A Harmonised Approach for Risk Assessment of Compounds which are both Genotoxic and Carcinogenic". Comments from the Norwegian Scientific Committee for Food Safety , 2005 .

[36]  K Walton,et al.  Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[37]  K Walton,et al.  Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. , 2005, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[38]  P. Wedlund The CYP2C19 Enzyme Polymorphism , 2000, Pharmacology.